PT-141 (Bremelanotide) research guide

PT-141 (Bremelanotide) in Israel — Sourcing Guide

Research-grade PT-141 (Bremelanotide) sourcing guide for Israel. COA verification, vendor selection, and handling protocols.

Browse Regions Order PT-141 (Bremelanotide) →

PT-141 (Bremelanotide) in Israel — Research Landscape

The PT-141 (Bremelanotide) research landscape in Israel connects to the same international vendor ecosystem — an international vendor market, community-based reputation systems and verification standards that apply universally. The practical sourcing landscape for Israel researchers is served almost exclusively by international vendors, concentrated in the US, Europe, and China — with varying quality standards across suppliers. Israel researchers entering this space benefit most from connecting with experienced researchers in Israel and globally as the safest starting point. Use this guide to evaluate PT-141 (Bremelanotide) vendors with Israel-specific context — combining the universal quality framework with country-specific considerations.

What the Literature Says About PT-141 (Bremelanotide)

The cosmetic peptide research area — including GHK-Cu and related compounds — has extensive commercial backing from the cosmetics industry, which has produced a large volume of in-vitro research data. Israel researchers accessing this literature should note that much of it is funded by cosmetic ingredient manufacturers and may be subject to publication bias toward positive results. Independent academic replication of key findings is important context. The mechanistic biology (copper cofactor role in collagen synthesis, MC1R activation in melanogenesis) is well-established regardless of commercial interests, but the magnitude of effects and optimal application conditions require careful evaluation of the specific literature.

Order PT-141 (Bremelanotide) in Israel
COA-verified · Ships to Israel · International tracking
Order Now →

Browse by Region

Top Cities in Israel

Israel PT-141 (Bremelanotide) Sourcing Guide

Israel researchers sourcing PT-141 (Bremelanotide) should factor in typical shipping timelines: international peptide shipments to Israel typically take roughly 5 to 15 working days depending on vendor location and shipping method. Request or retrieve batch-matched COAs for the specific PT-141 (Bremelanotide) product ahead of placing your order; verify HPLC purity is at or above 98%, mass spec confirmation, and bacterial endotoxin panel data. Storage infrastructure is a practical consideration Israel researchers should prepare before sourcing PT-141 (Bremelanotide) — lyophilised peptides require freezer-temperature storage at −20°C, and ordering more than your storage infrastructure can support is counterproductive. The three steps that cover the key sourcing risks for Israel researchers: peer reputation review, analytical document review, and confirmed shipping experience — these take minimal time but dramatically improve sourcing reliability.

Handling PT-141 (Bremelanotide) Safely

PT-141 (Bremelanotide) is a research compound unapproved for human therapeutic application — all information presented here is educational and intended for researchers. Storage requirements: lyophilised PT-141 (Bremelanotide) at −20°C, reconstituted solution stored refrigerated and used within 4 weeks — reconstitute only with bac water. From a pure handling safety perspective, PT-141 (Bremelanotide) presents the usual safety considerations for this class of compound — sterile technique, appropriate storage, and quality-verified source material are the key considerations.

Order PT-141 (Bremelanotide) — ships to Israel
COA-verified · International shipping · All compounds research grade
Order Now →

Frequently Asked Questions

What is the regulatory status of PT-141?

PT-141 (as Bremelanotide/Vyleesi) is an FDA-approved pharmaceutical in the US for HSDD in premenopausal women. This pharmaceutical status means it is more tightly regulated than pure research compounds in most jurisdictions. Import and possession regulations vary by country — verify current status in your jurisdiction before ordering.

How does PT-141 differ from Melanotan-2?

Both are melanocortin receptor agonists, but PT-141 is more selective for MC3R/MC4R (CNS-expressed receptors) while MT-2 has broader activity including MC1R (melanocytes) for pigmentation. PT-141 was specifically developed from MT-2 to have the CNS effects with reduced pigmentation side effects.

What is PT-141?

PT-141 (Bremelanotide) is a cyclic melanocortin receptor agonist developed from Melanotan-2. Unlike MT-2, PT-141 acts primarily on MC3R and MC4R receptors in the CNS rather than MC1R in melanocytes. It received FDA approval in 2019 as Vyleesi for hypoactive sexual desire disorder in premenopausal women. As a research compound it is studied for melanocortin receptor pharmacology.